

ARKANSAS KIDNEY DISEASE COMMISSION

Meeting Date: Wednesday June 8, 2011

Time: 12:30PM

Location/Room: ARS Little Rock Field Office - Conference Room

ATTENDEES:

Board Members Michael Bierle, MD; James Campbell, MD; Garry Glasco, MD; Kathy Pierce; Scott Young, MD; Bob Abbott; Curt Calaway

Guests Amy Bell, Jennifer Chunn, Steve Bryant; Mary Wilson; Bobby Walker; Mary A. Luttrell; Bonnie Bradley; Sarah Agee; Malanie Mechum; Nicole McCain

ARS Staff Jim Moreland; Richard Ward

AKDC Staff Katrina Betancourt; Helen Cobb

CALL TO ORDER

Dr. Garry Glasco declared a quorum and called the meeting to order.

MOTION TO ACCEPT MINUTES

Dr. Glasco requested Board Members to review the minutes of the last meeting. A motion to approve the minutes were declared. Mr. Abbott mentioned the corrected name for the Chain of Life Award recipient is Linda Tyler not (Linda Carter). The error was corrected and Dr. Glasco suggested a motion to approve the corrected minutes the board agreed, seconded and the motion passed.

COMMENTS FROM ARS COMMISSIONER ROBERT TREVIÑO

Due to legislative obligations Commissioner Treviño was not able to attend this meeting. Mr. Moreland conveyed the commissioner's apologies to the board at this time.

DR. GLASCO ASKED THE PROGRAM MANAGER TO PROVIDE THE BOARD WITH THE STATISTICAL REPORT.

STATISTICAL REPORT

Katrina Betancourt, Program Manager provided the Board an update regarding client statistical information. She reported that since the last Board meeting the AKDC having added 117 new clients with the program providing services to 1,122 individuals current fiscal year to date. She also provided a summary regarding the approval of clients for prior-approved drugs as well as pre-transplant dental services.

AKDC Clients

Clients Added Since Last Meeting	117
Clients Receiving Paid-for Services Last Fiscal Year	1141
Clients Receiving Paid-for Services Fiscal Year to Date	1122
Clients Receiving Prescription Drugs Fiscal Year to Date	953
Clients Receiving Pre-Transplant Dental Services	40
Clients Receiving Travel Reimbursement.....	129

AKDC Clients Receiving Prior-Approved Drugs

Clients Added to Renvela Approval List Since Last Meeting	16
Clients Added to Fosrenol Approval List Since Last Meeting.....	2

Clients Added to Sensipar Approval List Since Last Meeting	16
Clients Approved for Pre-Transplant Dental Services	10
Following discussion Ms. Betancourt provided the financial report.	

FINANCIAL REPORT

Ms Betancourt provided the Board an update of the AKDC's current financial information. She reported program client service expenditures fiscal year to date totaling \$826,704 with that number being down about \$90,000 when compared to the same time frame last fiscal year. She provided the Board an overview of expenditures including prescription drug and pre-transplant dental costs.

Previous Fiscal Year

Amount spent by the AKDC for Client Services Last Fiscal Year	\$ 885,314
Amount spent for Prescription Drugs	\$ 827,264
Amount spent for Pre-Transplant Dental Services	\$ 30,723
Amount of Nepro Purchased	\$ 27,327

Current Fiscal Year

AKDC Client Service Budget for State Fiscal Year	\$ 950,000
Amount Processed by the AKDC for Client Services Fiscal Year to Date	\$ 802,956
Amount Processed for Prescription Drugs	\$ 762,911
Amount Processed for Pre-Transplant Dental Services	\$ 21,550
Amount Processed for Transportation Reimbursement	\$ 18,495

Dr. Glasco asked Ms. Betancourt when fiscal year ends, she answered that it ends June 30th. He then asked if we under budget? Ms. Betancourt answered no, when everything is processed, we will be coming in at budget. He seemed satisfied with this assessment.

Ms. Betancourt explained that by next meeting the actual cost of Nepro will be forth coming.

At this time Dr. Young asked, since the cost of frames for the Chain of Life award was not included in the budget, are donations the reason? ... Ms. Betancourt answered yes.

Dr. Glasco wanted to know if there was a cost difference in transportation from last year to this year, it was explained, that this is our first year and due to the surplus of funds, we were able to provide transportation reimbursement to our clients for a three month period. Starting March 15th thru June 15th. Ms. Betancourt expressed that since this pilot study was successful, hopefully in the future with a few minor changes, we can possibly reinstate transportation reimbursement again.

With no other questions or comments on the financial report Dr. Glasco made a motion to approve the financial report. A motion was made, seconded and passed.

OLD BUSINESS

Chain of Life Award:

Ms. Betancourt happily announced that the awards were picked up as she held the actual award up for display, minus the two signatures agreed upon in a previous meeting. Ms. Betancourt explained that the next order of business is to schedule a meeting with Governor Beebe for his signature.

Dr. Young wanted to know if the press will be involved, Ms. Betancourt answered, hopefully.

With no other comments or questions concerning the Chain of Life Award, Dr. Glasco made a motion to approve. A motion was made and seconded.

Transportation:

Ms. Betancourt was of the opinion that the transportation reimbursements issued to our clients came at a good time especially due to the cost of gas. Ms. Betancourt shared that the estimated cost for travel is in the range of \$40,000.00 a quarter which is a stretch on our budget therefore preventing us from continuing with this assistance, she went on to explain that we wouldn't be able to maintain at that rate. Ms. Betancourt suggested we approach this dilemma another way perhaps by changing the mileage from ten miles to fifty miles round trip which will include travel three times a week starting from home to their dialysis unit and returning home. The changes will also entail refining other aspects of the program, hopefully to continue to with this type program. Ms. Betancourt shared that the clients were grateful and the social workers were very thankful.

With no further questions or comments concerning transportation... On to AAKP updates.

AAKP Convention:

Ms. Betancourt reported that AAKP is still working on sponsorship and has acquired a large sponsor The Amgen Corp. who provided \$45,000.00. Other smaller company has donated as well towards this event, she added that AKDC has been writing grants and so far The Genzyme company has donated a \$1,000. Since the funding of the event seems to be going well, she explained that the next hurdle is finding professional speakers that dialysis units has provided her with a list of patient willing to participate as speakers.

She explained the purpose for acquiring donations is to lesson the cost for registration which is \$135.00 for the three day event, that her goal is to cover \$100.00 of the fee in vouchers, that the patients will be required to pay \$35.00, she felt that if the patients were to pay this amount, it will help them to be more responsible and attend the event. She explained that the process was still in the making.

At this time she shared her major concern is getting AKDC clients to the event and asked the board for their assistance in getting the word and promoting the cause.

Ms. Betancourt added that so far the planning procedures and set-up for this event is progressing.

Dr. Glasco brought up his concerns for patients in the Helena area, Ms Betancourt shared that the units in the area were contacted and she was told they didn't have any patients that needed our assistance, she went on to explain that Referral Applications were sent out with followed up calls informing the units who we are and what services we offer, shortly afterwards, we've received several return applications for our services from this area. Visits are scheduled to visit dialysis units in Central Arkansas, the surrounding area as well as the West Helena area within the next several months.

Mr. Moreland commented that an experienced social worker familiar with our services has been assigned to the area; he went on to say that this should make a difference in the future.

No further questions or comments concerning Old Business was forth coming at this time.

New Business:

Dr. Glasco shared with the board that a new product has been introduced to the market called Phoslyra, he explained that it's a phosphorus binder that will be available in chewable tablet and liquid form, that it's expected to be on the market sometime in July, and more information will be forthcoming.

Nepro Purchase:

Mr. Betancourt informed the board that AKDC have enough funds left in its budget to purchased Nepro, she then asked for their approval to purchase the supplement, she explained that the amount of the purchase will be based on the Chief Financial Office's recommendation.

Ms. Betancourt shared with the board that last year's Nepro purchase was around \$30,000.00, that this year's cost is expected to be the same, however, the amount purchased will be based on the Chief Financial Officer's recommendation.

A motion was made and seconded to purchase Nepro through the proper channels.

With no other comments or questions forthcoming the motion was approved.

Election of the Chair and Co-Chair for AKDC:

Dr. Garry Glasco nominated Dr. Scott Young as the new Chairman for AKDC. The board approved the nomination a motion was made and seconded. Dr. Young was made the new Chairman of AKDC.

Curt Calaway was nominated for the new Co-Chair position, the board approved the nomination. A motion was made and seconded. Curt Calaway was made the new Co-Chair of AKDC.

2012 Board Meeting Schedule Dates:

Ms. Betancourt informed the board that a 2012 calendar was inserted into their notebook for their review, that the coordinating dates were marked for the next fiscal year, that the second Wednesday of the specific month for the meeting will remain the same.

After further discussion the quarterly dates were approved and the board was reminded that the next meeting will held on Wednesday September 14th at 12pm.

A motion was made to approve the dates for the next fiscal year. The motion was passed.

Announcements:

Dr.Glasco asked if there were any announcements, none were forthcoming.

A motion to adjourn the meeting is made and seconded.

The meeting was adjourned.

